XERECEPT Trademark

Trademark Overview

On Tuesday, October 14, 2025, a trademark application was filed for XERECEPT with the United States Patent and Trademark Office. The USPTO has given the XERECEPT trademark a serial number of 79439594. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, December 18, 2025. This trademark is owned by Curatis AG. The XERECEPT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary products, in particular medicines for cancer treatment and medicines for treatment of edema resulting from cancer.
xerecept

General Information

Serial Number79439594
Word MarkXERECEPT
Filing DateTuesday, October 14, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, December 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing0 - NOT AVAILABLE
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical and veterinary products, in particular medicines for cancer treatment and medicines for treatment of edema resulting from cancer.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 18, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCuratis AG
Party Type10 - Original Applicant
Legal Entity Type98 - Unknown
AddressCH

Trademark Events

Event DateEvent Description
Thursday, December 18, 2025SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

xerecept treatment cancer medicines resulting from edema veterinary pharmaceutical products particular